Academic Journal
Q1The Lancet Rheumatology
About The Lancet Rheumatology
The Lancet Rheumatology is a scholarly journal published by Elsevier Ltd. SCImago 2025 lists it in Q1, with an SJR of 6.167 and H-index of 66.
Coverage: 2019-2026. Research categories: Immunology (Q1); Immunology and Allergy (Q1); Rheumatology (Q1).
Journal Metrics
Metrics can change by reporting year. Verify time-sensitive values with the publisher or indexing service.
Aims & Scope
Scope information will be added after verification.
Recent Research Articles
Latest publications matched automatically by ISSN.
Prediction of psoriatic arthritis risk: watch for symptoms
Lihi Eder, Alexis Ogdie
2026-09 · DOI: 10.1016/s2665-9913(26)00182-7Secukinumab biosimilar BAT2306 versus reference secukinumab in patients with moderate-to-severe plaque psoriasis: a multicentre, double-blind, randomised, active-controlled, phase 3 trial
Jia-Qi Chen, Rongyi Chen, Liming Wu, Yangfeng Ding et al.
2026-09 · DOI: 10.1016/s2665-9913(26)00118-9Derivation, validation, and proposed thresholds of the Lupus Arthritis and Musculoskeletal Disease Activity (LAMDA) instrument: a cohort study
Samuel Wood, Khaled Mahmoud, Philip G Conaghan, Elizabeth M A Hensor et al.
2026-09 · DOI: 10.1016/s2665-9913(26)00208-0Beyond vasomotor symptoms: reframing musculoskeletal health in the Women's Health Strategy
Georgie M Massen, Catherine Borra, Jane E Hirst, Fiona E Watt et al.
2026-09 · DOI: 10.1016/s2665-9913(26)00260-2The GO TEST Overture Trial: is the evidence sufficient to guide primary care practice?
Hyon K Choi, Michael J Barry, Natalie McCormick, Chio Yokose et al.
2026-09 · DOI: 10.1016/s2665-9913(26)00214-6Infection risk in adults with secondary HLH
Naina McCann, Pratyasha Saha, Melissa Chowdhury, Ranya Ramadan et al.
2026-09 · DOI: 10.1016/s2665-9913(26)00224-9Translating progress into patient benefit in dermatomyositis
The Lancet Rheumatology
2026-09 · DOI: 10.1016/s2665-9913(26)00256-0Predicting psoriatic arthritis in new-onset psoriasis: development of multivariable prediction models from an inception cohort study
Axel Svedbom, Lotus Mallbris, Alen Zabotti, Martin P Playford et al.
2026-09 · DOI: 10.1016/s2665-9913(26)00115-3Prehabilitation in rheumatology: a missing link in psoriatic disease management
Ennio Lubrano, Fabio Massimo Perrotta, Mauro Fatica, Flavia Sunzini et al.
2026-09 · DOI: 10.1016/s2665-9913(26)00221-3The GO TEST Overture Trial: is the evidence sufficient to guide primary care practice? – Authors' reply
Anusha Moses, Martijn A H Oude Voshaar, Mart A F J van de Laar, Tim L Jansen et al.
2026-09 · DOI: 10.1016/s2665-9913(26)00216-xEfficacy and safety of rozanolixizumab in severe fibromyalgia: a phase 2A randomised, double-blind, placebo-controlled, multicentre trial
Andreas Goebel, Paul Meisner, Gustaf Rydevik, Alexander Vugler et al.
2026-09 · DOI: 10.1016/s2665-9913(26)00252-3Trends in autoimmune rheumatic disease diagnoses before and after the COVID-19 pandemic in England: a population-based cohort study using OpenSAFELY
Mark D Russell, Andrea Schaffer, Zijing Yang, Arti Mahto et al.
2026-09 · DOI: 10.1016/s2665-9913(26)00142-6BMI as a modifier of Janus kinase inhibitor response in rheumatoid arthritis
Chary Lopez Pedrera, Carlos Perez Sanchez
2026-09 · DOI: 10.1016/s2665-9913(26)00209-2Impact of BMI on response to Janus kinase inhibitors in rheumatoid arthritis: an individual patient data meta-analysis of randomised controlled trials
Katie Bechman, Mark D Russell, Kathryn Biddle, Mark Gibson et al.
2026-09 · DOI: 10.1016/s2665-9913(26)00151-7Progressive bone destruction of the hand in Gorham–Stout disease
Farzana Shumy, Kotaro Matsumoto
2026-09 · DOI: 10.1016/s2665-9913(25)00286-3Impact of the COVID-19 pandemic on autoimmune rheumatic disease diagnoses
Jeffrey A Sparks
2026-09 · DOI: 10.1016/s2665-9913(26)00177-3Low-dose and very low-dose glucocorticoids: which low is low risk?
Marc Scherlinger, Laurent Chiche
2026-09 · DOI: 10.1016/s2665-9913(26)00179-7When and how chronicity develops in rheumatoid arthritis: towards a temporal and tissue-integrated perspective
Alper Cevirgel, Annette H M van der Helm-van Mil
2026-09 · DOI: 10.1016/s2665-9913(26)00107-4Research in Brief
Jennifer Thorley
2026-09 · DOI: 10.1016/s2665-9913(26)00257-2Addressing the urgent need for clinical trials in chronic non-bacterial osteomyelitis
Christian M Hedrich, Eve Roberts, Giulia Inguscio, Athimalaipet V Ramanan et al.
2026-09 · DOI: 10.1016/s2665-9913(26)00156-6Reviews
Community Reviews
Version History
September 10, 2026 at 10:07 am
September 10, 2026